多西他赛联合洛铂或顺铂治疗晚期非小细胞肺癌的临床研究

Comparison between docetaxel combined with lobaplatin and cisplatin in the treatment of advanced non-small cell lung cancer

目的观察多西他赛联合洛铂与联合顺铂治疗晚期非小细胞肺癌（NSCLC）的疗效和毒副反应。方法将80例初治的晚期NSCLC患者,随机分为两组。观察组：多西他赛75 mg/m^2静滴,dI;洛铂30mg/m^2静滴,d 1。对照组：顺铂25 mg/m^2,静滴,d 1～3,多西他赛剂量及用法同上,21～28天为1周期。结果观察组患者的有效率和疾病控制率分别为42.5%（17/40）和80%（32/40）,对照组为47.5%（19/40）和82.5%（33/40）,差异均无统计学意义（P〉0.05）。在骨髓抑制和肝肾毒性方面,其差异无统计学意义（P〉0.05）;但观察组恶心、呕吐及便秘发生率明显低于对照组（χ^2=4.9,χ^2=6.42,P〈0.05）。结论多西他赛联合洛铂和顺铂治疗晚期NSCLC的临床疗效基本相似,但多西他赛联合洛铂毒副反应相对较低,病人更易耐受,值得进一步研究。

Objective To compare the clinical efficacy and toxicity of docetaxel combined with lobaplatin and cisplatin in treating advanced non-small cell lung cancer（ NSCLC）. Methods 80 patients with advanced NSCLC were randomly divided into two groups. The observation group（ n = 40） was given docetaxel 75 mg /m^2 iv drip,d1,and lobaplatin 30 mg /m^2 iv drip,d1. The control group（ n = 40） was docetaxel 75 mg /m^2 iv drip,d1,and cisplatin 25 mg /m^2,iv drip,dl-3. 21 ～ 28 days were a cycle. Results The effective rate and the disease control rate were 42. 5%（ 17 /40） and 80%（ 32 /40） in the observation group,and 47. 5%（ 19 /40） and 82. 5%（ 33 /40）in the control group respectively. There was no statistical difference between the two groups（ P〈0. 05）. The rates of marrow suppression and toxicity of liver and kidney were slightly lower in the observation group than in the control group（ P〈0. 05）,but the response rate of digestive system was significant lower in the observation group than in the control group（ χ^2= 4. 9,χ^2= 6. 42,P〈0. 05）. Conclusion The clinical efficacy of docetaxel combined with lobaplatin is similar with cisplatin in treating advanced NSCLC,but the reaction of toxicity is lower in docetaxel combined with lobaplatin compared with docetaxel combined with cisplatin,which is more tolerable and worthy of further study.